Normal view MARC view ISBD view

Dexmedetomidine promotes tumorigenicity via circular RNA BRAF/microRNA-381-3p /thrombospondin 2 in glioma

By: Cai, Lisong.
Contributor(s): Yajing, Zheng.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2023Edition: Vol.85(3), May-Jul.Description: 721-731p.Subject(s): PHARMACEUTICSOnline resources: Click here In: Indian journal of pharmaceutical sciencesSummary: Glioma is the most frequent primary intracranial tumor worldwide. Dexmedetomidine is an efficient anesthetic used in surgery and has an impact on glioma. Yet, the mechanism of dexmedetomidine on the biological characteristics of glioma cells is unknown. Circ_BRAF, microRNA-381-3p and thrombospondin 2 was detected via quantitative reverse transcription-polymer chine reaction. Proliferation detection was conducted using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and colony formation assay. Transwell assay was used to determine cell migratory and invasive capacities. The protein expression was determined using Western blot. Binding between microRNA- 381-3p and circ_BRAF or thrombospondin 2 was validated using dual-luciferase reporter. Role between dexmedetomidine and circ_BRAF on glioma growth was analyzed using the xenograft tumor model in mice. Dexmedetomidine inhibited circ_BRAF expression in glioma cells in a dose-dependent manner. Dexmedetomidine induced glioma cell proliferation, migration and invasion was neutralized via circ_ BRAF up regulation. Meanwhile, circ_BRAF could facilitate thrombospondin 2 expression via binding with miR-381-3p. Besides, dexmedetomidine was revealed to promote glioma tumourogenesis in vivo via circ_BRAF/ microRNA-381-3p/thrombospondin 2 pathways. Dexmedetomidine exposure expedited glioma development via circ_BRAF/microRNA-381-3p/thrombospondin 2 axis, providing a theoretical basis for glioma therapy.
Tags from this library: No tags from this library for this title. Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode Item holds
Articles Abstract Database Articles Abstract Database School of Pharmacy
Archieval Section
Not for loan 2024-0207
Total holds: 0

Glioma is the most frequent primary intracranial tumor worldwide. Dexmedetomidine is an efficient anesthetic used in surgery and has an impact on glioma. Yet, the mechanism of dexmedetomidine on the biological characteristics of glioma cells is unknown. Circ_BRAF, microRNA-381-3p and thrombospondin 2 was detected via quantitative reverse transcription-polymer chine reaction. Proliferation detection was conducted using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and colony formation assay. Transwell assay was used to determine cell migratory and invasive capacities. The protein expression was determined using Western blot. Binding between microRNA- 381-3p and circ_BRAF or thrombospondin 2 was validated using dual-luciferase reporter. Role between dexmedetomidine and circ_BRAF on glioma growth was analyzed using the xenograft tumor model in mice. Dexmedetomidine inhibited circ_BRAF expression in glioma cells in a dose-dependent manner. Dexmedetomidine induced glioma cell proliferation, migration and invasion was neutralized via circ_ BRAF up regulation. Meanwhile, circ_BRAF could facilitate thrombospondin 2 expression via binding with miR-381-3p. Besides, dexmedetomidine was revealed to promote glioma tumourogenesis in vivo via circ_BRAF/ microRNA-381-3p/thrombospondin 2 pathways. Dexmedetomidine exposure expedited glioma development via circ_BRAF/microRNA-381-3p/thrombospondin 2 axis, providing a theoretical basis for glioma therapy.

There are no comments for this item.

Log in to your account to post a comment.

Click on an image to view it in the image viewer

Unique Visitors hit counter Total Page Views free counter
Implemented and Maintained by AIKTC-KRRC (Central Library).
For any Suggestions/Query Contact to library or Email: librarian@aiktc.ac.in | Ph:+91 22 27481247
Website/OPAC best viewed in Mozilla Browser in 1366X768 Resolution.

Powered by Koha